The strategic vision of the European Medicines Agency (EMA) seeks to reinforce patient relevance in evidence generation for pharmaceutical products through a coordinated approach to PROMs collection. We recently conducted a study aimed at investigating the use of PROMs in new marketing authorizations for oncology drugs approved by the EMA between 2017 and 2021.
Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
Ciani, Oriana
;Meregaglia, Michela;
2023
Abstract
The strategic vision of the European Medicines Agency (EMA) seeks to reinforce patient relevance in evidence generation for pharmaceutical products through a coordinated approach to PROMs collection. We recently conducted a study aimed at investigating the use of PROMs in new marketing authorizations for oncology drugs approved by the EMA between 2017 and 2021.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
